Secondary Logo

Most Popular Articles

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study

Borden, Brittany A.; Galecki, Paige; Wellmann, Rebecca; More

Pharmacogenetics and Genomics. 29(2):31-38, February 2019.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics. 26(1):28-39, January 2016.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients

Etienne, Marie-Christine; Formento, Jean-Louis; Chazal, Maurice; More

Pharmacogenetics. 14(12):785-792, December 2004.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls

Tang, Yong Ming; Green, Bridgett L.; Chen, Gen-Fu; More

Pharmacogenetics. 10(9):761-766, December 2000.

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

Hall-Flavin, Daniel K.; Winner, Joel G.; Allen, Josiah D.; More

Pharmacogenetics and Genomics. 23(10):535-548, October 2013.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Griese, Ernst-Ulrich; Ilett, Kenneth F.; Kitteringham, Neil R.; More

Pharmacogenetics. 11(1):69-76, February 2001.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202

Verma, Anurag; Bradford, Yuki; Verma, Shefali S.; More

Pharmacogenetics and Genomics. 27(3):101-111, March 2017.

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia

Lopez-Lopez, Elixabet; Ballesteros, Javier; Piñan, Maria A.; More

Pharmacogenetics and Genomics. 23(2):53-61, February 2013.

The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

Oosterom, Natanja; Berrevoets, Marijn; den Hoed, Marissa A.H.; More

Pharmacogenetics and Genomics. 28(10):223-229, October 2018.

Severe toxicity and polymerase-γ gene abnormalities in Malawian adults on stavudine-based antiretroviral therapy

van Oosterhout, Joep J.; Gardner, Kristian; Mallewa, Jane; More

Pharmacogenetics and Genomics. 23(11):624-626, November 2013.

Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens–Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements

Okamoto-Uchida, Yoshimi; Nakamura, Ryosuke; Matsunaga, Kayoko; More

Pharmacogenetics and Genomics. 28(3):95-98, March 2018.

Genetic polymorphisms of cytochrome P450 2A6 in a case–control study on lung cancer in a French population

Loriot, Marie-Anne; Rebuissou, Sandra; Oscarson, Mikael; More

Pharmacogenetics. 11(1):39-44, February 2001.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β1 adrenergic receptor antagonist esmolol in healthy individuals

Muszkat, Mordechai; Hoofien, Assaf; Orlanski-Meyer, Esther; More

Pharmacogenetics and Genomics. 23(1):25-28, January 2013.

Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX

Fohner, Alison E.; Robinson, Renee; Yracheta, Joseph; More

Pharmacogenetics and Genomics. 25(7):343-353, July 2015.

Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism

Tanner, Julie-Anne; Zhu, Andy Z.; Claw, Katrina G.; More

Pharmacogenetics and Genomics. 28(1):7-16, January 2018.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Suvichapanich, Supharat; Fukunaga, Koya; Zahroh, Hilyatuz; More

Pharmacogenetics and Genomics. 28(7):167-176, July 2018.

Pharmacogenomic characterization of gemcitabine response – a framework for data integration to enable personalized medicine

Harris, Michael; Bhuvaneshwar, Krithika; Natarajan, Thanemozhi; More

Pharmacogenetics and Genomics. 24(2):81-93, February 2014.

Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide

Singh, Sonal; Wang, Zhiying; Shahin, Mohamed H.; More

Pharmacogenetics and Genomics. 28(11):251-255, November 2018.

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

Lubomirov, Rubin; Arab-Alameddine, Mona; Rotger, Margalida; More

Pharmacogenetics and Genomics. 23(1):9-18, January 2013.

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens–Johnson syndrome/toxic epidermal necrolysis in a Malaysian population

Chong, Huey Yi; Lim, Yi Heng; Prawjaeng, Juthamas; More

Pharmacogenetics and Genomics. 28(2):56-67, February 2018.

Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4)

Urban, Thomas J.; Yang, Chen; Lagpacan, Leah L.; More

Pharmacogenetics and Genomics. 17(9):773-782, September 2007.

Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism

Siccardi, Marco; D'Avolio, Antonio; Nozza, Silvia; More

Pharmacogenetics and Genomics. 20(12):759-765, December 2010.

Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy

Collins, Kimberly S.; Pratt, Victoria M.; Stansberry, Wesley M.; More

Pharmacogenetics and Genomics. 29(1):18-22, January 2019.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

Ingle, James N.; Kalari, Krishna R.; Wickerham, Donald Lawrence; More

Pharmacogenetics and Genomics. 28(6):147-152, June 2018.

Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers

Vandenberghe, Frederik; Saigí-Morgui, Núria; Delacrétaz, Aurélie; More

Pharmacogenetics and Genomics. 26(12):547-557, December 2016.

Cancer patients’ acceptance, understanding, and willingness-to-pay for pharmacogenomic testing

Cuffe, Sinead; Hon, Henrique; Qiu, Xin; More

Pharmacogenetics and Genomics. 24(7):348-355, July 2014.

The combination of mitochondrial low enzyme-activity aldehyde dehydrogenase 2 allele and superoxide dismutase 2 genotypes increases the risk of hypertension in relation to alcohol consumption

Nakagawa, Takehiro; Kajiwara, Ayami; Saruwatari, Junji; More

Pharmacogenetics and Genomics. 23(1):34-37, January 2013.